Still, the model will be tested in the next year or so, with contracts coming up for renewal for several of the most established anchors.
Hypothesis #1.1 (testing of the model) will be tested with path analysis modeling.
The calibration of the model will be tested with the Hosmer Lemeshow test[ 26].
Once built, the model will be tested and validated with empirical data, in order to analyze the goodness of fit.
The predictive power of the model will be tested with a selection of well-characterized chemicals with known health effects in animal studies.
This dataset will be comparable to the first regarding size and informative parameters and the model will be tested to verify its predictive value of the primary outcome: distal radius fracture.
The assumptions of the model will be tested by examination of the residuals, and the overall fit of the model will be ascertained using the Hosmer and Lemeshow goodness-of-fit model.
The assumptions of the model will be tested and reanalysed using a Q-Q plot diagram for the assumption of normality, and by comparing the studentised residuals versus the values of the independent variable for the assumption of constant variances.
Variations in the model will be tested, and those variables not having a significance p<0.05 in the Wald test will be eliminated when that does not involve a remarkable variation in the standardised β coefficients of the variables in the model.
The ECL model will be tested and the results will provide more accurate policy recommendations.
